Clinical Trial: Investigation of Anabolic and Catabolic Responses After a Single Bout of Exercise in Healthy Adults: Evaluation Using Urinary 3-Methylhistidine (Japan)

Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060824) titled 'Investigation of Anabolic and Catabolic Responses After a Single Bout of Exercise in Healthy Adults' on April 1.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Wakayama Medical University

Condition: Condition - Healthy adults Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - The objective of this study is to obtain basic knowledge for developing a safe and effective exercise prescription by comparing myokines, free amino acids in the blood, and urinary 3-methylhistidine (3-MH) levels before and after exercise in healthy individuals, with moderate aerobic and resistance exercise as the load conditions and suitable for patients. Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - Exercise Program Contents 1. Aerobic exercise: 40 minutes on a leg ergometer at 65% of peak VO2. 2. Resistance exercise: Bench press, bent-over row, squat, calf raise, 3 sets of 10 repetitions at 70% of 10RM for each exercise.

Eligibility: Age-lower limit - 20 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Adults aged 20 or over who are independent in activities of daily living Key exclusion criteria - Those with neurological symptoms, musculoskeletal diseases, or cardiorespiratory diseases that restrict daily life or work, those suspected of cognitive decline, pregnant women, smokers, those taking medication for lifestyle-related diseases such as hypertension, dyslipidemia, or diabetes, those with autoimmune diseases or chronic inflammatory diseases, those taking steroids/NSAIDs/anti-inflammatory supplements on an ongoing basis, those unable to give consent for the study, and others deemed unsuitable by the attending physician. Target Size - 20

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 03 Month 31 Day Anticipated trial start date - 2026 Year 04 Month 01 Day Last follow-up date - 2030 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069559

Disclaimer: Curated by HT Syndication.